Dual-Target-Directed Drugs that Block Monoamine Oxidase B and Adenosine A2A Receptors for Parkinson's Disease

Neurotherapeutics

Volumn 6, Issue 1, 2009, Pages 141-151

  Petzer, Jacobus P ^a   Castagnoli Jr , Neal ^b   Schwarzschild, Michael A ^c   Chen, Jiang Fan ^d   Van der Schyf, Cornelis J ^e  

^a NORTH WEST UNIVERSITY   (South Africa)

^b EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

adenosine A2A receptor; caffeine; dual target directed drug; monoamine oxidase B; Parkinson's disease

Indexed keywords

1,3 DIPROPYL 7 METHYL 8 [2 (3 THIENYL)ETHENYL]XANTHINE; 8 (3 CHLOROSTYRYL)CAFFEINE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; 8 (4 PHENYLBUTADIEN 1 YL)CAFFEINE; 8 [4 (3 CHLOROPHENYL)BUTADIEN 1 YL]CAFFEINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 8 STYRYLCAFFEINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CAFFEINE; CAFFEINE DERIVATIVE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; ISTRADEFYLLINE; LAZABEMIDE; LEVODOPA; METHYLXANTHINE; MONOAMINE OXIDASE B INHIBITOR; RASAGILINE; SAFINAMIDE; SELEGILINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; CLINICAL TRIAL; DOPAMINE METABOLISM; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; DYSKINESIA; HUMAN; MONOTHERAPY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OPTIMAL DRUG DOSE; PARKINSON DISEASE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIPARKINSON AGENTS; CENTRAL NERVOUS SYSTEM; DOPAMINE; DRUG THERAPY, COMBINATION; DYSKINESIAS; HAPLORHINI; HUMANS; LEVODOPA; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RECEPTORS, ADENOSINE A2; XANTHINES;

EID: 57749087002     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.10.035     Document Type: Article

References (115)

1. Allain H., Bentué-Ferrer D., and Akwa Y. Disease-modifying drugs and Parkinson's disease. Prog Neurobiol 84 (2008) 25-39
2. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
3. Lew M. Overview of Parkinson's disease. Pharmacotherapy 27 (2007) 155S-160S
4. Voss T., and Ravina B. Neuroprotection in Parkinson's disease: myth or reality?. Curr Neurol Neurosci Rep 8 (2008) 304-309
5. Chen J.J., and Swope D.M. Pharmacotherapy for Parkinson's disease. Pharmacotherapy 27 (2007) 161S-173S
6. Jankovic J., and Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 21 (2007) 677-692
7. Rezak M. Current pharmacotherapeutic treatment options in Parkinson's disease. Dis Mon 53 (2007) 214-222
8. Lees A. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 22 (2005) 731-740
9. Fernandez H.H., and Chen J.J. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy 27 (2007) 174S-185S
10. Youdim M.B., Collins G.G., Sandler M., Bevan Jones A.B., Pare C.M., and Nicholson W.J. Human brain monoamine oxidase: multiple forms and selective inhibitors. Nature 236 (1972) 225-228
11. Collins G.G., Sandler M., Williams E.D., and Youdim M.B. Multiple forms of human brain mitochondrial monoamine oxidase. Nature 225 (1970) 817-820
12. Di Monte D.A., DeLanney L.E., Irwin I., et al. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys. Brain Res 738 (1996) 53-59
13. Finberg J.P., Wang J., Bankiewicz K., Harvey-White J., Kopin I.J., and Goldstein D.S. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J Neural Transm Suppl 52 (1998) 279-285
14. Youdim M.B., and Bakhle Y.S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 147 (2006) S287-S296
15. Nicotra A., Pierucci F., Parvez H., and Senatori O. Monoamine oxidase expression during development and aging. Neurotoxicology 25 (2004) 155-165
16. Fowler J.S., Volkow N.D., Wang G.J., et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging 18 (1997) 431-435
17. Karolewicz B., Klimek V., Zhu H., et al. Effects of depression, cigarette smoking, and age on monoamine oxidase B in amygdaloid nuclei. Brain Res 1043 (2005) 57-64
18. Fowler C.J., Wiberg A., Oreland L., Marcusson J., and Winblad B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 49 (1980) 1-20
19. 2A receptor antagonists in Parkinson's disease. Pharmacol Ther 105 (2005) 267-310
20. 2A receptor antagonists. Life Sci 77 (2005) 3259-3267
21. 2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog Neurobiol 83 (2007) 293-309
22. 2A receptors in Parkinson's disease. Trends Neurosci 29 (2006) 647-654
23. 2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 184 (2003) 285-294
24. 2-selective adenosine antagonists. J Med Chem 36 (1993) 1333-1342
25. 2A-selective adenosine receptor antagonists. J Med Chem 40 (1997) 4396-4405
26. 2A receptor antagonism. J Biol Chem 277 (2002) 36040-36044
27. 2A receptor antagonists. Bioorg Med Chem 11 (2003) 1299-1310
28. 2A receptor antagonist (E)-8-(3-chlorostyryl) caffeine (CSC). Bioorg Med Chem 14 (2006) 3512-2351
29. Fredholm B.B., IJzerman A.P., Jacobson K.A., Klotz K.N., and Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53 (2001) 527-552
30. 2A receptors in the human brain by positron emission tomography with [11C]TMSX. Synapse 55 (2005) 133-136
31. 2-selective agonist, [3H]CGS 21680. Eur J Pharmacol 168 (1989) 243-246
32. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 57 (1991) 1062-1067
33. 2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 14 (1992) 186-195
34. 2 receptors in rat striatal membranes. Proc Natl Acad Sci USA 88 (1991) 7238-7241
35. Ferré S., O'Connor W.T., Fuxe K., and Ungerstedt U. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J Neurosci 13 (1993) 5402-5406
36. Ferré S., Fredholm B.B., Morelli M., Popoli P., and Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 20 (1997) 482-487
37. 2A antagonist: a novel anti-Parkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43 (1998) 507-513
38. 2 receptor knockout mice. Proc Natl Acad Sci USA 98 (2001) 1970-1975
39. 2A receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem 84 (2003) 1398-1410
40. 2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 321 (1997) 143-147
41. Jiang H., Jackson-Lewis V., Muthane U., et al. Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats. Brain Res 613 (1993) 347-351
42. 2A receptor antagonist in MPTP-treated monkeys. Neurology 52 (1999) 1673-1677
43. 2 dopamine agonists increases anti-Parkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 162 (2000) 321-327
44. 2A receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. Eur J Pharmacol 546 (2006) 82-87
45. 2A receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats. Neurosci Lett 251 (1998) 201-204
46. 2A antagonists with potent anti-cataleptic activity. Bioorg Med Chem Lett 18 (1997) 2349-2352
47. 2A receptor antagonist treatment of Parkinson's disease. Neurology 61 (2003) 293-296
48. 2A receptor antagonist istradefylline in advanced PD. Neurology 61 (2003) 297-303
49. 2A antagonist KW6002 from animal models to parkinsonian patients. Neurology 61 (2003) S107-S111
50. 2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 63 (2008) 295-302
51. Salamone J.D., Mayorga A.J., Trevitt J.T., Cousins M.S., Conlan A., and Nawab A. Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog Neurobiol 56 (1998) 591-611
52. Ascherio A., Zhang S.M., Hernán M.A., et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 50 (2001) 56-63
53. Ross G.W., Abbott R.D., Petrovitch H., et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283 (2000) 2674-2679
54. Powers K.M., Kay D.M., Factor S.A., et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord 23 (2008) 88-95
55. Ascherio A., Chen H., Schwarzschild M.A., Zhang S.M., Colditz G.A., and Speizer F.E. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 60 (2003) 790-795
56. 2A adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 21 (2001) RC143
57. 2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 80 (2002) 262-270
58. Joghataie M.T., Roghani M., Negahdar F., and Hashemi L. Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence. Parkinsonism Relat Disord 10 (2004) 465-468
59. 2A antagonist CSC in the 6-OHDA rat model of Parkinsonism: effect on the activity of striatal output pathways. Exp Brain Res 165 (2005) 362-374
60. 2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 39 (2001) 233-238
61. 2A adenosine receptors. J Neurosci 22 (2002) 1054-1062
62. 2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemi-Parkinsonian mice. J Neurosci 26 (2006) 13548-13555
63. Jalkanen S., and Salmi M. Cell surface monoamine oxidases: enzymes in search of a function. EMBO J 20 (2001) 3893-3901
64. Edmondson D.E., Binda C., and Mattevi A. The FAD binding sites of human monoamine oxidases A and B. Neurotoxicology 25 (2004) 63-72
65. Weyler W., Hsu Y.P., and Breakefield X.O. Biochemistry and genetics of monoamine oxidase. Pharmacol Ther 47 (1990) 391-417
66. Shih J.C., Chen K., and Ridd M.J. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci 22 (1999) 197-217
67. Youdim M.B., Edmondson D., and Tipton K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7 (2006) 295-309
68. Waldmeier P.C. Amine oxidases and their endogenous substrates (with special reference to monoamine oxidase and the brain). J Neural Transm Suppl 23 (1987) 55-72
69. Inoue H., Castagnoli K., Van Der Schyf C., Mabic S., Igarashi K., and Castagnoli Jr. N. Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinyl derivatives. J Pharmacol Exp Ther 291 (1999) 856-864
70. Weyler W., and Salach J.I. Purification and properties of mitochondrial monoamine oxidase type A from human placenta. J Biol Chem 260 (1985) 13199-13207
71. Saura J., Nadal E., van den Berg B., Vila M., Bombi J.A., and Mahy N. Localization of monoamine oxidases in human peripheral tissues. Life Sci 59 (1996) 1341-1349
72. Westlund K.N., Denney R.M., Kochersperger L.M., Rose R.M., and Abell C.W. Distinct monoamine oxidase A and B populations in primate brain. Science 230 (1985) 181-183
73. Kalaria R.N., Mitchell M.J., and Harik S.I. Monoamine oxidases of the human brain and liver. Brain 111 (1988) 1441-1451
74. Willoughby J., Glover V., Sandler M., Albanese A., Jenner P., and Marsden C.D. Monoamine oxidase activity and distribution in marmoset brain: implications for MPTP toxicity. Neurosci Lett 90 (1988) 100-106
75. Riachi N.J., and Harik S.I. Monoamine oxidases of the brains and livers of macaque and cercopithecus monkeys. Exp Neurol 115 (1992) 212-217
76. Levitt P., Pintar J.E., and Breakefield X.O. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA 79 (1982) 6385-6389
77. Fowler J.S., Logan J., Volkow N.D., Wang G.J., MacGregor R.R., and Ding Y.S. Monoamine oxidase: radiotracer development and human studies. Methods 27 (2002) 263-277
78. Birkmayer W., Riederer P., Youdim M.B., and Linauer W. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm 36 (1975) 303-326
79. Shoulson I., Oakes D., Fahn S., et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51 (2002) 604-612
80. Pålhagen S., Heinonen E.H., Hägglund J., et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology 51 (1998) 520-525
81. Stocchi F., Vacca L., Grassini P., et al. Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 67 (2006) S24-S29
82. Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol 40 (1996) 99-107
83. Pålhagen S., Heinonen E., Hägglund J., et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66 (2006) 1200-1206
84. Parkinson study group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson's disease. Arch Neurol 61 (2004) 561-566
85. Gesi M., Santinami A., Ruffoli R., Conti G., and Fornai F. Novel aspects of dopamine oxidative metabolism (confounding outcomes take place of certainties). Pharmacol Toxicol 89 (2001) 217-224
86. Fornai F., Giorgi F.S., Bassi L., Ferrucci M., Alessandrì M.G., and Corsini G.U. Modulation of dihydroxyphenylacetaldehyde extracellular levels in vivo in the rat striatum after different kinds of pharmacological treatment. Brain Res 861 (2000) 126-134
87. Marchitti S.A., Deitrich R.A., and Vasiliou V. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev 59 (2007) 125-150
88. Götz M.E., Freyberger A., and Riederer P. Oxidative stress: a role in the pathogenesis of Parkinson's disease. J Neural Transm Suppl 29 (1990) 241-249
89. Riederer P., Sofic E., Rausch W.D., et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52 (1989) 515-520
90. Grünblatt E., Mandel S., Jacob-Hirsch J., et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 111 (2004) 1543-1573
91. Chiba K., Trevor A., and Castagnoli Jr. N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120 (1984) 574-578
92. Heikkila R.E., Hess A., and Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224 (1984) 1451-1453
93. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
94. Heikkila R.E., Manzino L., Cabbat F.S., and Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311 (1984) 467-469
95. Collins M.A., and Neafsey E.J. Potential neurotoxic "agents provocateurs" in Parkinson's disease. Neurotoxicol Teratol 24 (2002) 571-577
96. Mandel S., Weinreb O., Amit T., and Youdim M.B. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev (2005) 379-387
97. Youdim M.B., Maruyama W., and Naoi M. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today (Barc) 41 (2005) 369-391
98. Maruyama W., Akao Y., Carrillo M.C., Kitani K., Youdium M.B., and Naoi M. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 24 (2002) 675-682
99. Carrillo M.C., Minami C., Kitani K., et al. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 67 (2000) 577-585
100. Kitani K., Kanai S., Ivy G.O., and Carrillo M.C. Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl: a possible antioxidant strategy. Mech Ageing Dev 111 (1999) 211-221
101. Fredholm B.B., Bättig K., Holmén J., Nehlig A., and Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51 (1999) 83-133
102. 3 adenosine receptor antagonists. Eur J Med Chem 38 (2003) 367-382
103. 2A receptor antagonists. Farmaco 56 (2001) 87-90
104. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl) 147 (1999) 90-95
105. 1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance. J Med Chem 36 (1993) 2508-2518
106. 2A receptor antagonist with anticataleptic activity. Eur J Pharmacol 256 (1994) 263-268
107. 2A adenosine receptor antagonists. Eur J Med Chem 31 (1996) 59-63
108. Van den Berg D., Zoellner K.R., Ogunrombi M.O., et al. Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues. Bioorg Med Chem 15 (2007) 3692-3702
109. 2A receptor antagonists. Neurology 61 (2003) S62-S68
110. 2A receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem 16 (2008) 8676-8684
111. Binda C., Newton-Vinson P., Hubálek F., Edmondson D.E., and Mattevi A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol 9 (2002) 22-26
112. Binda C., Li M., Hubálek F., Restelli N., Edmondson D.E., and Mattevi A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc Natl Acad Sci USA 100 (2003) 9750-9755
113. Hubálek F., Binda C., Khalil A., et al. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J Biol Chem 280 (2005) 15761-15766
114. Binda C., Wang J., Pisani L., et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 50 (2007) 5848-5852
115. Bolognesi M.L., Cavalli A., Valgimigli L., et al. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. J Med Chem 50 (2007) 6446-6449